Nyholm H C, Nielsen A L, Lyndrup J, Norup P, Thorpe S M
Department of Gynecology and Obstetrics, University of Copenhagen, Hvidovre Hospital, Denmark.
Am J Obstet Gynecol. 1992 Nov;167(5):1334-42. doi: 10.1016/s0002-9378(11)91712-8.
This study investigates clinicopathologic associations of estrogen and progesterone receptor content in endometrial carcinoma.
One hundred fifty-two patients with endometrial cancer and 12 with adenomatous hyperplasia were included. Dextran-coated charcoal receptor assay and immunohistochemical analysis were used. The immunohistochemical analysis receptor content was estimated semiquantitatively by a total and a cancer immunohistochemical histologic score. Multiple regression analysis was used in testing independence of established correlations.
Estrogen and progesterone receptor dextran-coated charcoal values and immunohistochemical histologic scores correlated inversely (p < 0.001) with International Federation of Gynecology and Obstetrics grade of tumor. An inverse correlation (p < 0.0001) between clinical stage and dextran-coated charcoal values was independent of International Federation of Gynecology and Obstetrics grade. Age of patient, years since menopause, and previous estrogen treatment were not related to receptor content. In adenomatous hyperplasia high progesterone receptor levels were seen.
The inverse correlation between clinical stage of endometrial carcinoma and content of estrogen and progesterone receptors may reflect tumor biologic behavior.
本研究调查子宫内膜癌中雌激素和孕激素受体含量的临床病理关联。
纳入152例子宫内膜癌患者和12例腺瘤样增生患者。采用葡聚糖包被活性炭受体分析法和免疫组织化学分析。免疫组织化学分析的受体含量通过总体和癌组织免疫组织化学组织学评分进行半定量评估。采用多元回归分析来检验已确定关联的独立性。
雌激素和孕激素受体的葡聚糖包被活性炭值及免疫组织化学组织学评分与国际妇产科联盟肿瘤分级呈负相关（p < 0.001）。临床分期与葡聚糖包被活性炭值之间的负相关（p < 0.0001）独立于国际妇产科联盟分级。患者年龄、绝经年限和既往雌激素治疗与受体含量无关。在腺瘤样增生中可见高孕激素受体水平。
子宫内膜癌临床分期与雌激素和孕激素受体含量之间的负相关可能反映肿瘤生物学行为。
